References

1. EMA.  Rare disease (orphan) designations- gevokizumab. Accessed on 02/04/2018. Modified on 02/04/2018. European Medicines Agency, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan_search.jsp&mid=WC0b01ac058001d12b&source=homeMedSearch&keyword=gevokizumab&isNewQuery=true

2. Geiler J, McDermott MF. (2010) Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther, 12 (6): 755-69. [PMID:21154167]

3. Issafras H, Corbin JA, Goldfine ID, Roell MK. (2014) Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties. J Pharmacol Exp Ther, 348 (1): 202-15. [PMID:24194526]

4. Masat L, Haak-Frendscho M, Chen G, Horwitz A, Roell M. (2009) IL-1β binding antibodies and fragments thereof. Patent number: US7531166. Assignee: Xoma Technology, Ltd. Priority date: 27/02/2015. Publication date: 12/03/2010.

5. Owyang AM, Issafras H, Corbin J, Ahluwalia K, Larsen P, Pongo E, Handa M, Horwitz AH, Roell MK, Haak-Frendscho M et al.. (2011) XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. MAbs, 3 (1): 49-60. [PMID:21048425]

6. Roell MK, Issafras H, Bauer RJ, Michelson KS, Mendoza N, Vanegas SI, Gross LM, Larsen PD, Bedinger DH, Bohmann DJ et al.. (2010) Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity. J Biol Chem, 285 (27): 20607-14. [PMID:20410301]

7. US FDA.  Gevokizumab orphan drug designations. Accessed on 02/04/2018. Modified on 02/04/2018. FDA Orphan Drug Designations and Approvals, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm